Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | ATM | Q13315 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.52 |
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4229252 | 0.89 | CA2 (0.55) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL28891118 | 0.88 | CA2 (0.53) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL318036 | 0.86 | CA2 (0.68) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL29475007 | 0.86 | CA2 (0.68) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL14288611 | 0.86 | CALM1 (0.61) | CA2ATMKDM4EALDH1A1ABCB1 | |
| SCHEMBL22472098 | 0.85 | CA2 (0.50) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL2611659 | 0.84 | CA2 (0.59) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL23458348 | 0.83 | CA2 (0.48) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL29640498 | 0.83 | CA2 (0.48) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL20326078 | 0.83 | CA2 (0.48) | CA2ATMKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630738-B1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2023-07-19 | — | — | EP | claimed |
| EP-3634970-B1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | LAURUS LABS LTD (IN) | 2023-07-19 | — | — | EP | claimed |
| US-20230057246-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | LAURUS LABS LIMITED (IN) | 2023-02-23 | — | — | US | claimed |
| EP-4099991-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | Laurus Labs Limited (IN) | 2022-12-14 | — | — | EP | claimed |
| US-20210323939-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | LAURUS LABS LIMITED (IN) | 2021-10-21 | — | — | US | claimed |
| WO-2021156811-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | LAURUS LABS LIMITED (IN) | 2021-08-12 | — | — | WO | claimed |
| US-11046676-B2 | Process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof | LAURUS LABS LIMITED (IN) | 2021-06-29 | — | — | US | claimed |
| US-20200131163-A1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | LAURUS LABS LIMITED (IN) | 2020-04-30 | — | — | US | claimed |
| EP-3634970-A1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | Laurus Labs Limited (IN) | 2020-04-15 | — | — | EP | claimed |
| EP-3630738-A1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | Egis Gyógyszergyár Zrt. (HU) | 2020-04-08 | — | — | EP | claimed |
| US-8901356-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2014-12-02 | — | — | US | claimed |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | Hogberg, Thomas (DK) | 2013-07-11 | — | — | US | claimed |
| EP-2595948-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2013-05-29 | — | — | EP | claimed |
| WO-2012131077-A1 | SOMATOSTATIN MIMETICS | NATIONAL UNIVERSITY OF IRELAND, GALWAY (IE) | 2012-10-04 | — | — | WO | claimed |
| US-20120214994-A1 | (3-FLUORO-2-HYDROXY)PROPYL-FUNCTIONALIZED ARYL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR THE DIAGNOSIS OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASES | FUTURECHEM CO., LTD. (KR) | 2012-08-23 | — | — | US | claimed |
| WO-2012010172-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO PHARMA A/S (DK) | 2012-01-26 | — | — | WO | claimed |
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | claimed |
| EP-2111400-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | AstraZeneca AB (SE) | 2009-10-28 | — | — | EP | claimed |
| US-20080171732-A1 | New Pyridine Analogues IX 519 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | claimed |
| WO-2008085117-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131163-A1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | SLC5A1, SLC5A2, DPP4 | CA2 745/4885ATM 3290/4885KDM4E 2674/4885 |
| US-20080171732-A1 | New Pyridine Analogues IX 519 | P2RY12, P2RY11, P2RY1 | CA2 2341/4885ATM 2805/4885KDM4E 3186/4885 |
| US-20230057246-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | CYP3A4, CYP4A11, CYP3A43 | CA2 3326/4885ATM 3677/4885KDM4E 647/4885 |
| US-20120214994-A1 | (3-FLUORO-2-HYDROXY)PROPYL-FUNCTIONALIZED ARYL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR THE DIAGNOSIS OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASES | APP, FABP7, SLC3A2 | CA2 1695/4885ATM 4508/4885KDM4E 3569/4885 |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | CA2 1415/4885ATM 2801/4885KDM4E 3559/4885 |
| US-11046676-B2 | Process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof | SLC5A2, SLC5A1, DPP4 | CA2 548/4885ATM 3418/4885KDM4E 2529/4885 |
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | P2RY12, P2RY11, P2RY1 | CA2 2193/4885ATM 2086/4885KDM4E 4200/4885 |
| US-20210323939-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | SLC5A1, SLC5A2, DPP4 | CA2 429/4885ATM 3306/4885KDM4E 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.